Althea, CMO, also known as Ajinomoto Althea, Inc., is a fully integrated contract development and manufacturing organization (CDMO) specializing in biopharmaceutical services. Established in 1998 and headquartered in San Diego, California, the company offers comprehensive services including process development, drug substance manufacturing, and drug product manufacturing. Althea is recognized for its expertise in aseptic fill-finish operations for vials and syringes, catering to both early-stage clinical requirements and commercial manufacturing needs.
Key Strategic Focus
Althea's strategic focus lies in providing end-to-end solutions for biopharmaceutical companies, emphasizing:
- Process Development: Offering upstream and downstream process development to optimize manufacturing processes.
- Drug Substance Manufacturing: Specializing in microbial-based manufacturing of recombinant proteins and plasmid DNA.
- Drug Product Manufacturing: Executing drug formulation and aseptic fill-finish for vials and syringes.
The company targets the biotechnology and pharmaceutical sectors, aiming to support clients from early clinical stages through to commercial production.
Financials and Funding
As of July 2024, Althea reported annual revenues between $50 million and $100 million. The company has raised a total of $23 million over three funding rounds, with the latest round occurring on January 10, 2007.
Technological Platform and Innovation
Althea distinguishes itself through several proprietary technologies and methodologies:
- Crystalomics: A proprietary formulation technology that offers solutions for large molecule products requiring high concentrations or sustained release formulations.
- cGMP Manufacturing: Maintaining compliance with current Good Manufacturing Practices (cGMP) to ensure product quality and regulatory adherence.
- Aseptic Fill-Finish: Expertise in aseptic processing for vials and syringes, ensuring sterility and product integrity.
These capabilities enable Althea to deliver high-quality biopharmaceutical products efficiently.
Leadership Team
Althea's leadership comprises experienced professionals dedicated to advancing the company's mission:
- Chief Scientific Officer: R. G.
- Vice President of Human Resources: E. R.
- Vice President of Compliance: L. J. M.
These leaders bring extensive expertise in biopharmaceutical development and manufacturing, guiding Althea's strategic initiatives.
Leadership Changes
On April 24, 2025, Althea was acquired by PCI Pharma Services, marking a significant transition in the company's ownership and strategic direction.
Competitor Profile
Market Insights and Dynamics
The biopharmaceutical CDMO market is characterized by robust growth, driven by increasing demand for biologics and complex therapeutics. Key trends include a focus on specialized manufacturing capabilities, regulatory compliance, and technological innovation.
Competitor Analysis
Althea operates in a competitive landscape alongside several key players:
- Ajinomoto Bio-Pharma Services: A global CDMO offering a range of services from process development to commercial manufacturing.
- Oxford BioTherapeutics: Develops medicines for cancer and companion diagnostics for selected antibody programs.
- CytomX Therapeutics: Focuses on oncology therapeutics based on Probody technology.
- ADC Therapeutics: Specializes in drug conjugates for treating solid and hematological cancers.
- Lexicon Pharmaceuticals: Develops therapeutic products for diseases related to immunology, metabolism, cardiology, and ophthalmology.
These competitors emphasize innovation, specialized services, and global reach, contributing to a dynamic and competitive market environment.
Strategic Collaborations and Partnerships
Althea has engaged in strategic partnerships to enhance its service offerings and market position. Notably, the acquisition by PCI Pharma Services in April 2025 is expected to expand Althea's capabilities and global reach, leveraging PCI's extensive resources and expertise.
Operational Insights
Althea's integrated service model, combining process development with manufacturing and fill-finish capabilities, provides a competitive advantage by offering clients a seamless transition from development to commercialization. The company's commitment to cGMP compliance and proprietary technologies like Crystalomics further differentiate it in the market.
Strategic Opportunities and Future Directions
Under the ownership of PCI Pharma Services, Althea is poised to explore new growth avenues, including expanding its service portfolio, entering new geographic markets, and investing in advanced manufacturing technologies. These strategic initiatives aim to strengthen Althea's position as a leading CDMO in the biopharmaceutical industry.
Contact Information
- Website: altheacmo.com
- LinkedIn: Althea, CMO
For further inquiries, please visit the company's official website or LinkedIn profile.
